La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Vir Biotechnology a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Vir Biotechnology..

Vir Biotechnology (NASDAQ:VIR) Azioni, Catena delle Opzioni

VIR BIOTECHNOLOGY INC

Vir Biotechnology

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Vir Biotechnology Inc

Virtu Financial, Inc. Class A Common Stock

Virtu Financial Inc

Virco Manufacturing Corporation - Common Stock

Virco Manufacturing Corp

Viratech Corp

Neuralbase AI Ltd

Viridien

Viracta Therapeutics Inc

Press Releases

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma

Akebia Therapeutics

AnaptysBio

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

CareDx

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Erasca

Geron

Gyre Therapeutics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Keros Therapeutics

Kura Oncology

MeiraGTx Hldgs

Myriad Genetics

Nurix Therapeutics

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Rezolute

Tango Therapeutics

Tyra Biosciences

UroGen Pharma

Xencor

HC Wainwright & Co.

Evercore ISI Group

B of A Securities

Raymond James

Needham

Comments

Vir Biotechnology

Vir Biotechnology (VIR) Opzioni

Vir Biotechnology (NASDAQ:VIR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO